• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>RPC

RPC

  1. All
  2. Morningstar Articles
  3. 3rd Party
  1. Verseon Reveals Preclinical Data on Novel Drug Candidates to Treat Diabetic Macular Edema

    Verseon Reveals Preclinical Data on Novel Drug Candidates to Treat Diabetic Macular Edema

  2. Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

    Chi-Med Initiates a Phase I/II Clinical Trial of Novel FGFR Inhibitor HMPL-453 in China

  3. Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell ...

    Ipsen and its partner Exelixis announce independent radiology committee review confirms results from Phase 2 CABOSUN trial of cabozantinib versus sunitinib in previously untreated advanced renal cell carcinoma

  4. Perfect365 Hosts First-Ever Digital Giorgio Armani Beauty at Nordstrom

    Perfect365 Hosts First-Ever Digital Giorgio Armani Beauty at Nordstrom

  5. Perfect365 Partners with NYX Professional Makeup For Virtual Makeup Try-On at PHAMExpo

    Perfect365 Partners with NYX Professional Makeup For Virtual Makeup Try-On at PHAMExpo

  6. A New Performance Footwear Company, Q4 Sports, Arrives on the Scene Just When It Matters Most

    A New Performance Footwear Company, Q4 Sports, Arrives on the Scene Just When It Matters Most

  7. 2017 Goddard School Franchise Disclosure Document (FDD) - Research and Markets

    2017 Goddard School Franchise Disclosure Document (FDD) - Research and Markets

12345

©2017 Morningstar Advisor. All right reserved.